Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
Nuclear Medicine
FDG
Name:
18F FDG Radiofarma®
Active Principle:
Deoxiglucose Fluor
Therapeutic Action:
It is indicated for the measurement of glucose metabolism, the diagnosis of primary, recurrent or metastatic disease of various tumors and for the study of cardiomyopathies, osteoarthropathies and neurological lesions.
RELATED PRODUCTS
-
123I MIBG BACON (R&D)
123I MIBG BACON (R&D)It is indicated for: Oncology: a) Scintigraphic localization of tumors originating in tissues that derive embryologically from the neural crest... -
PYROPHOSPHATE
PYROPHOSPHATEIt is indicated for performing bone scintigraphy, detection of cardiac pathologies and "in vivo" and "in vitro" marking of erythrocytes. 1) In vivo, in vitro or in vivo/in vitro marking of red blood cells to... -
TECHNETIUM GENERATOR
TECHNETIUM GENERATORIt is indicated for obtaining a solution of Sodium Pertechnetate (Tc99m) ... -
IODOSOL 123I (R&D)
IODOSOL 123I (R&D)Sodium iodide (123I) solution is indicated as a diagnostic agent to evaluate thyroid function and/or morphology by scintigraphy and radioactive iodine uptake test.

